Sincalide (Kinevac): Uses, Mechanism, and Reported Effects

Anyone scheduled for a gallbladder or pancreatic function test may come across sincalide without knowing what it does. This peptide is not a treatment itself but a diagnostic tool that helps clinicians visualize and assess digestive organ function.

Key takeaways

• Sincalide is a cholecystokinin (CCK) analog marketed as Kinevac, used in adults for diagnostic procedures.
• It works by stimulating gallbladder contraction and pancreatic secretion, mimicking the body's natural hormone.
• The label does not carry a boxed warning.
• Thirteen registered trials have studied sincalide, including work in neonates and gallbladder physiology research.
• FAERS reports for sincalide are dominated by product performance issues rather than classic adverse reactions.

What Sincalide Is

Sincalide belongs to a drug class called cholecystokinin analogs. It is a synthetic version of a peptide fragment of the natural hormone cholecystokinin. When given intravenously, it stimulates the gallbladder to contract and empty, an effect similar to what happens naturally after eating. It also stimulates pancreatic secretion, slows gastric emptying, and causes pyloric contraction, which affects how quickly material moves through the intestinal tract.

What Sincalide Is Approved For

Kinevac is approved in adults for several diagnostic uses rather than for treating a disease. It is used to stimulate gallbladder contraction so that imaging methods can assess gallbladder function, and it can help obtain a bile sample by duodenal aspiration for analysis of cholesterol, bile salts, phospholipids, and crystals. It is also used alongside secretin to stimulate pancreatic secretion before collecting a duodenal aspirate for enzyme and cytology analysis. A further approved use is accelerating the transit of a barium meal through the small bowel, which can shorten the time and radiation exposure needed for fluoroscopy and x-ray exams of the intestinal tract. The label does not carry a boxed warning.

What the Evidence Shows

Thirteen trials involving sincalide are registered. One completed study compared sincalide against placebo in neonates at high risk of developing cholestasis associated with parenteral nutrition. Another completed trial examined how gallbladder emptying and bile acids triggered by sincalide relate to GLP-1 secretion in humans.

Reported Side Effects

Reports submitted to FAERS for sincalide are counts of adverse event reports, not confirmed rates or proof of causation. Many of the most frequent reports relate to product performance rather than bodily reactions, including drug ineffectiveness, decreased drug effect, multiple use of a single-use product, and product quality issues. Some reports noted no adverse event at all. Among reports describing physical symptoms, nausea and diarrhoea appear most often, consistent with sincalide's effects on gastrointestinal motility.